PYXS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.306

+16.59%

-0.300

-14.29%

-0.280

-6.67%

Estimates Revision

The market is revising Upward the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 1.07% over the past three months. During the same period, the stock price has changed by -52.43%.

Revenue Estimates for FY2025

Revise Upward

+1.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.57%

In Past 3 Month

Stock Price

Go Down

-52.43%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.57 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

7.57

High

9.00

Current: 0.000

Low

5.00

Averages

7.57

High

9.00

RBC Capital

Leonid Timashev

Outperform

NULL

downgrade

$8 -> $5

2025-12-19

Reason

RBC Capital

Leonid Timashev

Price Target

$8 -> $5

2025-12-19

downgrade

Outperform

NULL

Reason

RBC Capital analyst Leonid Timashev lowered the firm's price target on Pyxis Oncology to $5 from $8 and keeps an Outperform rating on the shares. The company reported phase 1 data from their micvo mono and combo trials in recurrent/metastatic head and neck squamous cell carcinoma, and there was a lot to digest in this update - efficacy that looks like it beat the bar, combinatorial synergy potential, and potential for further optimization, balanced against a smaller than expected update and a high adverse effect and discontinuation rate, the analyst tells investors in a research note. The complexity of the dataset may explain the downward move, but there is likely a sufficient therapeutic window to navigate a path forward as combo data at lower doses may on its own provide enough of an opportunity to support its fair value estimate, the firm added.

H.C. Wainwright

Buy

maintain

$5 -> $7

2025-12-19

Reason

H.C. Wainwright

Price Target

$5 -> $7

2025-12-19

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Pyxis Oncology to $7 from $5 and keeps a Buy rating on the shares after the company provided a clinical data update on studies evaluating Micvo as a therapy for relapsed/metastatic head and neck squamous cell carcinoma. The firm says the "consistent" efficacy and "manageable" safety profile increase its confidence in the second-line setting.

Stephens

Loganathan

Overweight

maintain

$5 -> $8

2025-11-24

Reason

Stephens

Loganathan

Price Target

$5 -> $8

2025-11-24

maintain

Overweight

Reason

Stephens analyst Sudan Loganathan raised the firm's price target on Pyxis Oncology to $8 from $5 and keeps an Overweight rating on the shares, citing "growing conviction" around MICVO and its potential to be a competitive treatment option for recurrent or metastatic head and neck squamous cell carcinoma.

Stifel

Stephen Willey

Buy

initiated

2025-11-03

Reason

Stifel

Stephen Willey

Price Target

2025-11-03

initiated

Buy

Reason

Stifel analyst Stephen Willey resumed coverage of Pyxis Oncology with a Buy rating and $9 price target. The firm believes micvotabart pelidotin is "a convention-defying ADC intentionally designed to better-optimize what Enhertu achieves serendipitously" and believes Phase 1 dose-escalation data establishes clear mechanistic proof-of-concept, the analyst tells investors. The firm sees year-end disclosure of preliminary MICVO data supporting a registration-directed effort as a second-line and later SCCHN agent in a competitively-nascent, soon-to-be multi-billion-dollar total addressable market, the analyst added.

Guggenheim

Buy

initiated

2025-09-04

Reason

Guggenheim

Price Target

2025-09-04

initiated

Buy

Reason

Guggenheim initiated coverage of Pyxis Oncology with a Buy rating and $5 price target. The firm believes the market may incorrectly written off micvotabart pelidotin, a first-in-concept non-internalizing antibody-drug conjugate against the novel target extra-domain B splice variant of fibronectin in the tumor stroma. The analyst thinks Pyxis may have a viable development path for micvotabart.

Guggenheim

Buy

initiated

2025-09-03

Reason

Guggenheim

Price Target

2025-09-03

initiated

Buy

Reason

Guggenheim initiated coverage of Pyxis Oncology with a Buy rating and $5 price target.

Valuation Metrics

The current forward P/E ratio for Pyxis Oncology Inc (PYXS.O) is -0.87, compared to its 5-year average forward P/E of -1.93. For a more detailed relative valuation and DCF analysis to assess Pyxis Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.93

Current PE

-0.87

Overvalued PE

-0.36

Undervalued PE

-3.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.40

Undervalued EV/EBITDA

-1.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

66.77

Current PS

0.00

Overvalued PS

217.52

Undervalued PS

-83.99

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PYXS News & Events

Events Timeline

No data

News

9.5

01-08NASDAQ.COM

ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept

9.0

2025-12-19Benzinga

Experts Raise Concerns About Pyxis Oncology's Small Clinical Trial

6.0

2025-12-19Benzinga

Tesla's Price Target of $444? Check Out 10 Leading Analyst Predictions for Friday

People Also Watch

Frequently Asked Questions

What is Pyxis Oncology Inc (PYXS) stock price today?

The current price of PYXS is 1.76 USD — it has increased 21.38 % in the last trading day.

What is Pyxis Oncology Inc (PYXS)'s business?

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

What is the price predicton of PYXS Stock?

What is Pyxis Oncology Inc (PYXS)'s revenue for the last quarter?

Pyxis Oncology Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Pyxis Oncology Inc (PYXS)'s earnings per share (EPS) for the last quarter?

Pyxis Oncology Inc. EPS for the last quarter amounts to -0.35 USD, decreased -0.00 % YoY.

What changes have occurred in the market's expectations for Pyxis Oncology Inc (PYXS)'s fundamentals?

How many employees does Pyxis Oncology Inc (PYXS). have?

Pyxis Oncology Inc (PYXS) has 44 emplpoyees as of January 10 2026.

What is Pyxis Oncology Inc (PYXS) market cap?

Today PYXS has the market capitalization of 109.92M USD.